Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.41
+1.8%
$3.87
$2.70
$11.55
$8.60M2.2628,700 shs7,134 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$2.46
-4.3%
$4.11
$2.37
$48.79
$7.66M7.94391,241 shs52,494 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+1.85%+20.82%+8.89%+42.26%-60.77%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-4.28%-7.52%-44.97%-54.44%-69.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.49N/AN/A$13.18 per share0.33
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$13.80M0.53N/AN/A$0.22 per share11.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$13.58M-$11.05N/AN/A-98.42%-665.17%-122.48%6/13/2024 (Estimated)

Latest VVOS, NURO, and NVCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A-$3.05-$3.05-$3.05N/A$3.25 million    
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A
0.34
0.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Insider Ownership

CompanyInsider Ownership
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
9.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
1542.98 million2.70 millionOptionable

VVOS, NURO, and NVCN Headlines

SourceHeadline
Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval
proactiveinvestors.com - April 11 at 3:32 PM
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
finance.yahoo.com - April 9 at 6:42 PM
Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices
markets.businessinsider.com - April 9 at 1:41 PM
Whats Going On With Vivos Therapeutics Stock?What's Going On With Vivos Therapeutics Stock?
msn.com - April 9 at 1:41 PM
Medicare to reimburse for Vivos CARE sleep apnea devicesMedicare to reimburse for Vivos CARE sleep apnea devices
msn.com - April 9 at 1:41 PM
Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursementVivos Therapeutics CARE oral medical devices approved for Medicare reimbursement
proactiveinvestors.com - April 9 at 9:31 AM
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
investorplace.com - April 9 at 8:53 AM
Vivos Therapeutics files to sell 1.73M shares of common stock for holdersVivos Therapeutics files to sell 1.73M shares of common stock for holders
msn.com - April 9 at 8:41 AM
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
finance.yahoo.com - April 9 at 8:41 AM
Vivos Therapeutics Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
globenewswire.com - April 9 at 7:30 AM
Verve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety ReportVerve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety Report
precisionmedicineonline.com - April 2 at 5:52 PM
Vivos Therapeutics highlights path to cash flow positivity after FDA clearanceVivos Therapeutics highlights path to cash flow positivity after FDA clearance
proactiveinvestors.com - April 1 at 9:07 AM
Vivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsVivos Therapeutics Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 31 at 1:42 PM
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 30 at 12:38 PM
Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss
marketwatch.com - March 29 at 1:13 AM
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
globenewswire.com - March 28 at 4:05 PM
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
globenewswire.com - March 28 at 7:30 AM
Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report
benzinga.com - February 22 at 12:09 PM
Vivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesVivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades
benzinga.com - February 22 at 7:09 AM
Vivos Therapeutics secures $4 million through warrant exerciseVivos Therapeutics secures $4 million through warrant exercise
investing.com - February 18 at 12:39 AM
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
finance.yahoo.com - February 15 at 9:27 AM
Vivos Therapeutics sees gross proceeds of $4M from exercise of warrantVivos Therapeutics sees gross proceeds of $4M from exercise of warrant
proactiveinvestors.com - February 15 at 9:13 AM
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions
finance.yahoo.com - February 12 at 9:45 AM
Vivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
finanznachrichten.de - February 6 at 10:18 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
Vivos Therapeutics logo

Vivos Therapeutics

NASDAQ:VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.